Is Beta Drugs the Best Stock in Its Sector? A Look at the Numbers

Is Beta Drugs the best stock in its sector? The stock trades on the NSE at Rs 2,188 as of 24 September 2026, within its 52-week range of Rs 990.10 to Rs 2,807.90. Beta Drugs Ltd manufactures oncology and specialty injectable pharmaceutical formulations.

Beta Drugs sits in the Healthcare sector, and its 16.95% ROE and 52.41x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Beta Drugs

Beta Drugs Ltd manufactures oncology and specialty injectable pharmaceutical formulations. It manufactures oncology and specialty injectable formulations, a higher-margin, higher-barrier segment of pharma manufacturing than generic oral solids. At a market capitalisation of Rs 2,425 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Beta Drugs the Best Stock in Its Sector?

Beta Drugs makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 16.95% ROE with a 52.41x P/E against the sector's 38.33x Industry P/E. Beta Drugs' 52.41x P/E is above the 38.33x Industry P/E, a premium built on its 16.95% ROE and oncology and injectables specialisation, well ahead of Bal Pharma's return profile in this comparison.

Metric	Beta Drugs
CMP (NSE)	Rs 2,187.80
52-Week High / Low	Rs 2,807.90 / Rs 990.10
Market Cap	Rs 2,425 Cr
P/E (TTM) vs Industry P/E	52.41x vs 38.33x
P/B	9.87
ROE	16.95%
EPS (TTM)	Rs 41.74
Dividend Yield	0.00%
Debt to Equity	0.60

Compare Beta Drugs Against Other Healthcare Sector Stocks

How Beta Drugs Compares Against Its Healthcare Sector Peers

The table below sets Beta Drugs against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Beta Drugs	2,425	52.41	16.95%	0.60
Bal Pharma	172	23.72	7.64%	1.94
Anuh Pharma	942	21.32	11.65%	0.00
Peer average (2 companies)	-	22.52	9.64%	0.97

Against this peer set, Beta Drugs's 16.95% ROE is above the 9.64% peer average, and its P/E of 52.41x runs above the peer average of 22.52x. Beta Drugs' 52.41x P/E is above the 38.33x Industry P/E, a premium built on its 16.95% ROE and oncology and injectables specialisation, well ahead of Bal Pharma's return profile in this comparison.

What Makes Beta Drugs Worth Watching in Healthcare

• Strong ROE: A 16.95% ROE is well above most generic formulation makers covered in this series.
• Oncology and injectables specialisation: Focusing on oncology and specialty injectable formulations gives Beta Drugs a higher-margin, higher-barrier manufacturing niche.
• Above Industry P/E: A 52.41x P/E against a 38.33x Industry P/E reflects a premium for its specialised, higher-margin product mix.

Beta Drugs Valuation: Is It Justified?

Beta Drugs' 52.41x P/E is above the 38.33x Industry P/E, a premium built on its 16.95% ROE and oncology and injectables specialisation, well ahead of Bal Pharma's return profile in this comparison. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is AWL Agri Business the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Beta Drugs and other Healthcare sector stocks.

How to Track Beta Drugs Before You Invest

Before deciding whether Beta Drugs deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Beta Drugs to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Beta Drugs earns a place in the best stock in its sector conversation on the strength of a 16.95% ROE and a P/E of 52.41x against a 38.33x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Beta Drugs the best stock in its sector?

Ans. Beta Drugs has a 16.95% ROE and trades at 52.41x P/E against a 38.33x Industry P/E, and compares above the peer average ROE of 9.64% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Beta Drugs?

Ans. Beta Drugs was trading at Rs 2,187.80 on the NSE as of 24 September 2026, within its 52-week range of Rs 990.10 to Rs 2,807.90.

What sector does Beta Drugs belong to?

Ans. Beta Drugs is classified under the Healthcare sector on Univest.

How does Beta Drugs compare to its sector peers on P/E?

Ans. Beta Drugs's P/E of 52.41x is above the 22.52x average of the 2 named peers compared in this article.

What is Beta Drugs's return on equity?

Ans. Beta Drugs reported a return on equity of 16.95%, which is above the 9.64% average of its named peers in this comparison.

Should I invest in Beta Drugs based on its sector position?

Ans. Beta Drugs's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.